menu
    • menu

    Company profile for Cellenkos

    NEW Drugs in Dev: 6
    FAMAR CDMO- From early development to commercial manufacturing.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Together we can improve the quality of life

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2025-11-03

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Cellenkos is a clinical-stage biotechnology company focused on cellular therapies for the treatment of inflammatory disorders and autoimmune diseases. Cellenkos is founded on technologies arising from the laboratory investigations of Simrit Parmar, MD, Associate Professor in the Department of Lymphoma and Myeloma at the University of Texas at MD Anderson Cancer Center.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    CellenkosUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    5416 Chaucer Drive, Houston, TX 77005
    Telephone
    Telephone
    (800) 217-8247
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.cellenkosinc.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Cosmoprof

    Cosmoprof

    Not Confirmed

    envelop Contact Supplier

    Cosmoprof

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Grants Orphan Designation to Cellenkos' CK0804 Treg Therapy
    FDA Grants Orphan Designation to Cellenkos' CK0804 Treg Therapy

    06 Jan 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-cellenkos-ck0804-treg-therapy-for-treatment-of-myelofibrosis-302653827.html

    PR NEWSWIRE
    06 Jan 2026
    Share Share
    CK0804 Cuts Spleen Volume, Transfusions in Myelofibrosis
    CK0804 Cuts Spleen Volume, Transfusions in Myelofibrosis

    10 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dose-intensive-ck0804-regimen-reduces-spleen-volume-and-transfusion-needs-in-jak-inhibitorresistant-suboptimal-myelofibrosis-with-thrombocytopenia-302637978.html

    PR NEWSWIRE
    10 Dec 2025
    Share Share
    FDA Grants Orphan Status To Cellenkos' CK0803 Tregs For ALS
    FDA Grants Orphan Status To Cellenkos' CK0803 Tregs For ALS

    20 Oct 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/fda-grants-orphan-drug-designation-to-cellenkos-ck0803-tregs-for-treatment-of-amyotrophic-lateral-sclerosis-302588514.html

    PR NEWSWIRE
    20 Oct 2025
    Share Share
    Cellenkos Showcases CK0804 Phase 1b Data For Myelofibrosis
    Cellenkos Showcases CK0804 Phase 1b Data For Myelofibrosis

    10 Dec 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/12/10/2994370/0/en/Cellenkos-Presents-Phase-1b-Data-at-ASH-2024-Showcasing-the-Potential-of-T-Regulatory-Cell-Therapy-Candidate-CK0804-for-Myelofibrosis.html

    GLOBENEWSWIRE
    10 Dec 2024
    Share Share
    Cellenkos Announces to Present at ASH on CK0804 in Myelofibrosis
    Cellenkos Announces to Present at ASH on CK0804 in Myelofibrosis

    07 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/cellenkos-announces-oral-presentation-at-ash-annual-meeting-2024-highlighting-phase-1b-clinical-data-of-ck0804-in-myelofibrosis-302298808.html

    PR NEWSWIRE
    07 Nov 2024
    Share Share
    Cellenkos links with Mount Sinai to explore CK0804 for myelofibrosis
    Cellenkos links with Mount Sinai to explore CK0804 for myelofibrosis

    02 Apr 2024

    // PHARMACEUTICAL TECHNOLOGY

    https://www.pharmaceutical-technology.com/news/cellenkos-mount-ck0804/

    PHARMACEUTICAL TECHNOLOGY
    02 Apr 2024
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search